Literature DB >> 23727278

Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.

Sunil Kumar Tripathi1, Ravikumar Muttineni, Sanjeev Kumar Singh.   

Abstract

Molecular docking, free energy calculation and molecular dynamics (MD) simulation studies have been performed, to explore the putative binding modes of 3,5-diaminoindazoles, imidazo(1,2-b)pyridazines and triazolo(1,5-a) pyridazines series of Cyclin-dependent kinase (CDK2) inhibitors. To evaluate the effectiveness of docking protocol in flexible docking, we have selected crystallographic bound compound to validate our docking procedure as evident from root mean square deviations (RMSDs). We found different binding sites namely catalytic, inhibitory phosphorylation, cyclin binding and CKS-binding site of the CDK2 contributing towards the binding of these compounds. Moreover, correlation between free energy of binding and biological activity yielded a statistically significant correlation coefficient. Finally, three representative protein-ligand complexes were subjected to molecular dynamics simulation to determine the stability of the predicted conformations. The low value of the RMSDs between the initial complex structure and the energy minimized final average complex structure suggests that the derived docked complexes are close to equilibrium. We suggest that the phenylacetyl type of substituents and cyclohexyl moiety make the favorable interactions with a number of residues in the active site, and show better inhibitory activity to improve the pharmacokinetic profile of compounds against CDK2. The structure-based drug design strategy described in this study will be highly useful for the development of new inhibitors with high potency and selectivity.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Binding free energy; Biological activity; Cell-cycle; Glide XP docking; MM-GBSA

Mesh:

Substances:

Year:  2013        PMID: 23727278     DOI: 10.1016/j.jtbi.2013.05.014

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  27 in total

1.  Targeting the cyclin-binding groove site to inhibit the catalytic activity of CDK2/cyclin A complex using p27(KIP1)-derived peptidomimetic inhibitors.

Authors:  Arumugasamy Karthiga; Sunil Kumar Tripathi; Ramasamy Shanmugam; Venkatesan Suryanarayanan; Sanjeev Kumar Singh
Journal:  J Chem Biol       Date:  2014-09-18

2.  Pyrazolo[3,4-d]pyrimidines as novel inhibitors of O-acetyl-L-serine sulfhydrylase of Entamoeba histolytica: an in silico study.

Authors:  Umesh Yadava; Bindesh Kumar Shukla; Mihir Roychoudhury; Devesh Kumar
Journal:  J Mol Model       Date:  2015-03-25       Impact factor: 1.810

3.  Computational biophysics approach towards the discovery of multi-kinase blockers for the management of MAPK pathway dysregulation.

Authors:  Muthu Kumar Thirunavukkarasu; Shanthi Veerappapillai; Ramanathan Karuppasamy
Journal:  Mol Divers       Date:  2022-10-19       Impact factor: 3.364

4.  Identification of an Inhibitor of the Aminoglycoside 6'-N-Acetyltransferase type Ib [AAC(6')-Ib] by Glide Molecular Docking.

Authors:  Kevin Chiem; Saumya Jani; Brooke Fuentes; David L Lin; Madeline E Rasche; Marcelo E Tolmasky
Journal:  Medchemcomm       Date:  2015-11-03       Impact factor: 3.597

5.  Drug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine.

Authors:  Hsin-Chieh Tang; Calvin Yu-Chian Chen
Journal:  Biomed Res Int       Date:  2014-06-19       Impact factor: 3.411

6.  A combined experimental and computational study of Vam3, a derivative of resveratrol, and Syk interaction.

Authors:  Ming Jiang; Renping Liu; Ying Chen; Qisheng Zheng; Saijun Fan; Peixun Liu
Journal:  Int J Mol Sci       Date:  2014-09-25       Impact factor: 5.923

7.  An in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2.

Authors:  Tomer Meirson; Abraham O Samson; Hava Gil-Henn
Journal:  Drug Des Devel Ther       Date:  2017-05-18       Impact factor: 4.162

8.  Hybrid In Silico and TR-FRET-Guided Discovery of Novel BCL-2 Inhibitors.

Authors:  Kader Sahin; Muge Didem Orhan; Timucin Avsar; Serdar Durdagi
Journal:  ACS Pharmacol Transl Sci       Date:  2021-04-15

9.  Inhibition of acetylcholinesterase by two genistein derivatives: kinetic analysis, molecular docking and molecular dynamics simulation.

Authors:  Jiansong Fang; Ping Wu; Ranyao Yang; Li Gao; Chao Li; Dongmei Wang; Song Wu; Ai-Lin Liu; Guan-Hua Du
Journal:  Acta Pharm Sin B       Date:  2014-11-22       Impact factor: 11.413

Review 10.  Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.

Authors:  Yan Li; Jingxiao Zhang; Weimin Gao; Lilei Zhang; Yanqiu Pan; Shuwei Zhang; Yonghua Wang
Journal:  Int J Mol Sci       Date:  2015-04-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.